KalVista Pharmaceuticals (KALV) News Today → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free KALV Stock Alerts $11.44 -0.13 (-1.12%) (As of 08:47 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKalVista Pharmaceuticals Appoints William C. Fairey to Board of Directorsbusinesswire.com - April 22 at 6:30 AMBrokers Set Expectations for KalVista Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:KALV)americanbankingnews.com - April 19 at 3:01 AMLeerink Partnrs Weighs in on KalVista Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:KALV)marketbeat.com - April 18 at 6:31 AMKalVista Pharmaceuticals (NASDAQ: KALV)fool.com - April 17 at 6:10 PMKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Updateamericanbankingnews.com - April 16 at 3:12 AMVanguard Group Inc. Acquires 151,808 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)marketbeat.com - April 15 at 4:15 AMKalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 13 at 6:16 AMAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)markets.businessinsider.com - April 11 at 1:25 PMKalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Needham & Company LLCmarketbeat.com - April 11 at 8:31 AMAnalysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)markets.businessinsider.com - April 3 at 5:17 PMKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conferencebusinesswire.com - April 3 at 6:30 AMKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 2 at 6:30 AMKalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volumemarketbeat.com - March 28 at 7:27 PMKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americasfinance.yahoo.com - March 18 at 11:00 AMResearch Analysts Offer Predictions for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)marketbeat.com - March 18 at 2:43 AMKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Up 50.8% in Februarymarketbeat.com - March 16 at 5:36 PMLeerink Partnrs Comments on KalVista Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:KALV)marketbeat.com - March 15 at 7:22 AMFY2024 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Lifted by HC Wainwrightmarketbeat.com - March 14 at 6:57 AMKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Forecasted to Earn Q1 2025 Earnings of ($0.57) Per Sharemarketbeat.com - March 13 at 6:50 AMBuy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE Treatmentmarkets.businessinsider.com - March 12 at 2:22 PMKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstatfinance.yahoo.com - March 12 at 9:21 AMBuy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista Pharmaceuticalsmarkets.businessinsider.com - March 11 at 9:51 AMKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Updatebusinesswire.com - March 11 at 6:30 AMKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americasfinanznachrichten.de - March 8 at 9:57 AMKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americasbusinesswire.com - March 8 at 6:30 AMKalVista Pharmaceuticals Stock Falls After CEO Resignsmarketwatch.com - March 7 at 7:26 PMKalVista Stock Drops After Announcement Of Resignation Of CEO Andrew Crockettmarkets.businessinsider.com - March 7 at 2:26 PMKalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, Directormarketwatch.com - March 7 at 8:34 AMKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officerbusinesswire.com - March 7 at 6:30 AMKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conferencebusinesswire.com - March 6 at 6:30 AMKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 4 at 6:30 AMKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Large Growth in Short Interestmarketbeat.com - March 4 at 12:34 AMMPM Bioimpact LLC Has $5.57 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)marketbeat.com - March 1 at 10:19 AMAnalysts Set Expectations for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)marketbeat.com - February 29 at 9:29 AMKalVista reports high efficacy for HAE drug in phase 3 trialinvesting.com - February 28 at 12:46 AMKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meetingfinance.yahoo.com - February 27 at 9:45 AMKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meetingbusinesswire.com - February 27 at 6:30 AMKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meetingbusinesswire.com - February 26 at 6:30 AMKalVista Pharmaceuticals (KALV) Price Target Increased by 51.92% to 32.23msn.com - February 25 at 1:33 AMKalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstatfinance.yahoo.com - February 20 at 10:47 AMKalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstatbusinesswire.com - February 20 at 6:30 AMKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meetingfinance.yahoo.com - February 16 at 10:37 AMFY2024 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Cut by Analystmarketbeat.com - February 16 at 9:23 AMKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meetingbusinesswire.com - February 16 at 6:30 AMKalVista Is Still Cheap After Phase 3 Hereditary Angioedema Dataseekingalpha.com - February 15 at 1:17 PMKalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 52-Week High on Analyst Upgrademarketbeat.com - February 15 at 10:25 AMKalVista Pharmaceuticals up 16%, prices $160M offeringmsn.com - February 15 at 8:15 AMKalVista Prices Offering Of $160 Mln Of Shares; Stock Up Over 14% In Pre-marketmarkets.businessinsider.com - February 15 at 8:15 AMKalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrantsfinance.yahoo.com - February 15 at 8:15 AMKalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrantsbusinesswire.com - February 15 at 6:30 AM Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address At first glance, this chart looks like nonsense… (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates” But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… KALV Media Mentions By Week KALV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼1.030.46▲Average Medical News Sentiment KALV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼72▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLRN News OCS News CALT News ABUS News PAHC News TBPH News ALT News TVTX News LRMR News IGMS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
